Silence Therapeutics Plc American Depository Share
SLNStock
$10.92−72.00%52W
Market Cap$493.60M
P/E—
Div yield—
Beta2.40
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-36.42%
Price vs S&P 500 (4W)-31.71%
VGM Score30.21
Market Capitalization$493.60M
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
SLNSilence Therapeutics Plc American Depository Share | F | D | C | $10.92 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Silence Therapeutics is a biotechnology company developing short-interfering RNA (siRNA) therapeutics using its proprietary mRNAi GOLD platform. The company's pipeline targets cardiovascular disease, hematology, and rare diseases, with lead candidates Divesiran for hematological disorders and Zerlasiran for cardiovascular conditions. Silence also generates revenue through out-licensed programs with third-party collaborators.